Severe congenital neutropenia (SCN)
characterized by congenital neutropenia and maturation arrest in
myeloid series is an orphan disorder with estimated prevalence
of 6 per million [1]. Homozygous or compound heterozygous
mutations in G6PC3 gene, which encodes
glucose-6-phosphatase enzyme, constitute around 2% of cases of
SCN (MIM 612541) [2,3]. Till date, around 60 patients of this
deficiency have been described in literature [4]. Majority
of G6PC3 deficiency are syndromic and associated with prominent
superficial veins, cardiac, genitourinary and renal disorders.
Dursun syndrome has additional features involving non-myeloid
hematopoietic cell lines, extra-hematologic features and
pulmonary hypertension [1]. Recently, a non-syndromic phenotype
has been described [4,5]. We describe a novel mutation
associated with non-syndromic G6PC3 deficiency.
A five-month-old girl of southern Indian ethnicity,
second born of second degree consanguineous marriage (birth
weight 2600 gm) presented with multiple episodes of septicemia,
pneumonia, acute gastroenteritis, and otitis media. She had a
BCG scar and was developmentally normal. On examination,
anthropometry revealed severe wasting (weight 4 kg, length 63
cms). There was no dysmorphism and hepato-splenomegaly.
Her hemoglobin records ranged from 8.5 to 10 g/dL
with normal mean corpuscular volume, persistent neutropenia with
absolute neutrophil count (ANC) between 100-1500/cmm and
intermittent thrombo-cytopenia (nadir platelet count
1,10,000/cmm). Bone marrow examination revealed cellular marrow
with maturation arrest at myelocyte stage; erythrocytes and
megakaryocytes were normal. In view of recurrent infections with
pancytopenia, differential diagnoses considered were primary
immunodeficiency, inherited bone marrow failure syndrome and
autoimmune neutropenia. Immunoglobulin profile was normal [IgG
889 (176-581) mg/dL, IgM 95 (24-102) mg/dL, IgA 99 (4-58)
mg/dL]. HIV-ELISA and direct Coombs test were negative.
Chromosome 22qdel by FISH was negative. T and NK cell subsets,
CH50 screening test for complement pathway defect,
dihydrorhodamine test were normal. Immunophenotyping of thymic
function and anti-neutrophilic antibodies for auto-immune
neutropenia were unavailable.
Anti-tissue transglutaminase IgA and TORCH titres were
normal. Chromosomal breakage studies and stool for fat globules
were negative. Ultrasound was not suggestive of pancreatic
fibrosis or renal anomaly. Targeted clinical exome sequencing by
next generation sequencing was sent for congenital neutropenia.
A homozygous single base pair deletion in exon 3 of the G6PC3
gene variant c.372delC that results in a frameshift and
premature truncation of the protein at codon 125 was detected.
Echocardiography did not reveal any structural heart disease or
pulmonary hypertension.
Brainstem evoked response audiometry suggested mild
hearing loss.
She was managed with antibiotic, antiviral and
antifungal prophylaxis with granulocyte-colony stimulating
factor (G-CSF) at 5µg/kg/day. After G-CSF, ANC improved to
>1500/cmm without recurrence of any severe infection in next 6
months. Parents were counseled regarding the disease and were
advised to avoid live vaccines. There was no donor available for
bone marrow transplant. A trial off G-CSF was attempted at one
year age. Parents were advised to use G-CSF if ANC fell below
500/cmm. At two
years of age, ANC was between 1000-2000/cmm with no reported
severe bacterial infections. She had normal development and
growth, with weight and height presently between 10-25th
centile. She did not require any further courses of
G-CSF.
G6PC3
gene maps to 17q21.31, consists of six exons and encodes the
G6PC3 protein. Homozygous missense mutations leading to
frameshifts are described in four out of six reported non-
syndromic cases. The largest number of missense mutations have
been described in exon 6 [5]. Index child had deletion mutation
in exon 3 which is a novel mutation in G6PC3 responsible
for SCN. G6PC3 mutation causes G6PC3 deficiency affecting
Glucose-6-phoshatase enzyme activity resulting in increased
apoptosis of neutrophils leading to maturation arrest,
subsequent neutropenia and diminished respiratory burst thereby
accounting for both quantitative and qualitative defect in
neutrophils [4]. A phenotypic heterogeneity and founder effect
in Pakistani ethnicity has recently been described [4,5].
The typical hematological features described are
severe neutropenia starting in early infancy and maturation
arrest in myeloid lineage or myelokathexis. Dysfunctional
neutrophilic activity, anemia, lympho-penia and intermittent
thrombocytopenia are additional hematologic findings.
So far only six non-syndromic cases have been described in
literature [1,4,5]. Index child did not have any of the above
syndromic features. It remains unclear whether growth failure
was primary or secondary to recurrent infections. Similarly,
sensorineural hearing loss is described in just three cases till
date and has not been shown to be syndromically associated [4].
In the index child it may be attributed to recurrent ear
infections. A prominent superficial venous pattern described in
around two-third of the patient may not be present in infancy
and becomes prominent with age. Non-syndromic presenta-tion of
G6PC3 deficiency should thus always be thought of in a child
with isolated congenital neutropenia [1].
The genetic diagnosis is important in SCN as phenotypic
variability exists; wherein most severe cases may require early
bone marrow transplant (BMT), while rest may require G-CSF and
infection prophylaxis awaiting a definitive BMT.
Chronic G-CSF therapy has been inconsistently reported to
be associated with myelodysplastic syndrome/myeloid leukemia and
may not correct functional deficiency of neutrophil despite
reversing neutropenia to a safer limit [6].
The use of G-CSF without clinical benefit should be
avoided.
To conclude, SCN-4 should be considered in differential
diagnosis of early onset severe neutropenia and indiscriminate
use of G-CSF should be curtailed unless clinically indicated.
Contributors:
SK: concept, patient care and manuscript drafting;
SuKP, SKP: Patient care and final manuscript drafting.
Funding:
None; Competing interest: None stated.
References
1. Donadieu J, Fenneteau O,
Beaupain B, Mahlaoui N, Chantelot CB. Congenital neutropenia:
Diagnosis, molecular bases and patient management. Orphanet J
Rare Dis. 2011;6:26.
2. Boztug K, Appaswamy G,
Ashikov A, Schäffer AA, Salzer U, Diestelhorst J, et al.
A syndrome with congenital neutropenia and mutations in G6PC3. N
Engl J Med. 2009;360:32-43.
3. Xia J, Bolyard AA, Rodger
E, Stein S, Aprikyan AA, Dale DC, et al. Prevalence of
mutations in ELANE, GFI1, HAX1, SBDS, WAS and G6PC3 in patients
with severe congenital neutropenia. Br J Haematol.
2009;147:535-42.
4. Banka S, Wynn R, Byers H,
Arkwright PD, Newman WG. G6PC3 mutations cause non-syndromic
severe congenital neutropenia. Mol Genet Metab. 2013;108:138-41.
5. Banka S, Chervinsky E,
Newman WG, Crow YJ, Yeganeh S, Yacobovich J, et al.
Further delineation of the phenotype of severe congenital
neutropenia type 4 due to mutations in G6PC3. Eur J Hum Genet.
2011;19:18-22.
6. Rosenberg PS, Alter BP,
Bolyard AA, Bonilla MA, Boxer LA, Cham B, et al. The
incidence of leukemia and mortality from sepsis in patients with
severe congenital neutropenia receiving long-term G-CSF therapy.
Blood. 2006; 107:4628-35.